Recently funded actions and current calls in the field of red biotechnology and regenerative medicine under the health cluster of the EU framework programme horizon Europe.

IF 2.1 4区生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology Letters Pub Date : 2025-09-12 DOI:10.1007/s10529-025-03639-8

Bernd Walter Rainer

引用次数: 0

Abstract

Health-related biotechnology and regenerative medicine are prominent fields for research funding under the European Framework Programme. Based on a bibliometric analysis of projects funded under the current Horizon Europe Programme an overview of scientifically top-ranking projects is presented. The classical collaborative research scheme represented by the Health Cluster prevails in terms of funding source. Biotechnology and regenerative medicine have been recognised as promising fields at both the global and European levels and this is also reflected in the current calls for research proposals in the Health Cluster under Horizon Europe.

查看原文本刊更多论文

在欧盟框架方案地平线欧洲卫生组项下，最近资助了红色生物技术和再生医学领域的行动和当前呼吁。

与健康有关的生物技术和再生医学是欧洲框架方案提供研究经费的重要领域。基于对当前“欧洲地平线计划”资助的项目的文献计量分析，本文概述了科学上排名最高的项目。以卫生集群为代表的经典合作研究计划在资金来源方面占主导地位。生物技术和再生医学在全球和欧洲都被认为是有前途的领域，这也反映在“欧洲地平线”下的卫生集群目前的研究建议呼吁中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Letters 工程技术-生物工程与应用微生物

CiteScore

5.90

自引率

3.70%

发文量

108

审稿时长

1.2 months

期刊介绍： Biotechnology Letters is the world’s leading rapid-publication primary journal dedicated to biotechnology as a whole – that is to topics relating to actual or potential applications of biological reactions affected by microbial, plant or animal cells and biocatalysts derived from them. All relevant aspects of molecular biology, genetics and cell biochemistry, of process and reactor design, of pre- and post-treatment steps, and of manufacturing or service operations are therefore included. Contributions from industrial and academic laboratories are equally welcome. We also welcome contributions covering biotechnological aspects of regenerative medicine and biomaterials and also cancer biotechnology. Criteria for the acceptance of papers relate to our aim of publishing useful and informative results that will be of value to other workers in related fields. The emphasis is very much on novelty and immediacy in order to justify rapid publication of authors’ results. It should be noted, however, that we do not normally publish papers (but this is not absolute) that deal with unidentified consortia of microorganisms (e.g. as in activated sludge) as these results may not be easily reproducible in other laboratories. Papers describing the isolation and identification of microorganisms are not regarded as appropriate but such information can be appended as supporting information to a paper. Papers dealing with simple process development are usually considered to lack sufficient novelty or interest to warrant publication.